IDEXX Laboratories, Inc. $IDXX Shares Sold by Davis R M Inc.

Davis R M Inc. trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 95,588 shares of the company’s stock after selling 5,775 shares during the period. IDEXX Laboratories accounts for approximately 1.1% of Davis R M Inc.’s portfolio, making the stock its 26th largest position. Davis R M Inc. owned about 0.12% of IDEXX Laboratories worth $61,070,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in IDXX. EverSource Wealth Advisors LLC raised its stake in IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after acquiring an additional 15 shares during the last quarter. STF Management LP grew its stake in shares of IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares during the last quarter. Clearstead Trust LLC increased its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in shares of IDEXX Laboratories by 3.3% during the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after purchasing an additional 17 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. This trade represents a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 20,873 shares of company stock valued at $13,408,523 in the last three months. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Trading Down 0.6%

Shares of IDXX opened at $656.73 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $52.29 billion, a P/E ratio of 50.25, a PEG ratio of 3.99 and a beta of 1.66. The firm’s 50-day moving average is $672.95 and its two-hundred day moving average is $669.12.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.